CRISPR Q3 net loss $174.5M; exa-cel rolling FDA review starts Nov, EMA/MHRA by year-end

CRISPR Therapeutics AG

2022-Q3 EPS reported -$6.96 revenue$1,192,000

CRISPR Q3 net loss $174.5M, cash $1.97B; R&D spend up to $116.6M.
Exa-cel rolling FDA review starts Nov; complete submission due Q1 2023; EMA/MHRA submissions by year-end.
CTX112 (next-gen CAR-T) IND cleared; Phase 1 expected H1 2023.
VCTX211 (T1D stem-cell therapy) CTA cleared by Health Canada.
CTX110 pivotal trial ongoing; CTX130 RMAT designation for CTCL; additional data expected in 2022.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CRISPR Therapeutics AG reported third quarter ended September 30, 2022 results: revenue $0.1 million.

Period: third quarter ended September 30, 2022
Revenue: $0.1 million
Result: reported results

Exact text from the filing

Revenue: Total collaboration revenue was $0.1 million for the third quarter of 2022, compared to $0.3 mill

View on SEC.gov

Browse all earnings releases →

CRISPR Therapeutics AG filing history →

Source: SEC EDGAR

accession 0000950170-22-020834

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.